Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

0
Player Avatar acumulator (< 20) Submitted: 8/20/2012 7:46:10 PM : Outperform Start Price: $1.26 ZLCS Score: -69.50

The potential for good news on there pain drug Synavive, could move the price of this stock up in the next several months which could make this a good trade.

Featured Broker Partners


Advertisement